Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. Academic Article uri icon

start page

  • 1

end page

  • 9

abstract

  • There is uncertainty regarding the onset timing of the cognitive deficiencies of schizophrenia. We investigated whether conversion to psychosis and/or olanzapine altered the neuropsychological course of subjects within the first-ever double blind medication study of the putative schizophrenia first episode prodrome.Sixty participants in a double blind trial of olanzapine as a treatment for putative prodromal states were assessed at entry (pre-randomization), and again at 6 and 12 months (if they remained non-psychotic), or at any of these points prior to psychosis followed by post-psychosis and 6 months post-psychosis assessments.Participants who converted to psychosis did not differ from placebo non-converters in pre-randomization global neuropsychological status. Early converters did not differ from later converters in entry neuropsychological status. Subjects who converted after 6 months did not show neuropsychological declines during the initial, pre-psychosis, 6 months. Neuropsychological course did not differ between converters to psychosis and non-converters, or between olanzapine and placebo-assigned subjects.Neither the onset of frank psychosis nor olanzapine treatment of the prodrome significantly alters neuropsychological course in persons considered to be at high risk at their initial (pre-psychosis) assessment. These findings suggest that the neuropsychological deficiencies associated with psychotic conditions largely pre-exist the first frank psychotic episode.

date/time value

  • October 2008

Digital Object Identifier (DOI)

  • 10.1016/j.schres.2008.07.008

PubMed Identifier

  • 18774696

volume

  • 105

number

  • 1-3

keywords

  • Adolescent
  • Antipsychotic Agents
  • Benzodiazepines
  • Cognition
  • Cognition Disorders
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Neuropsychological Tests
  • North America
  • Placebos
  • Psychiatric Status Rating Scales
  • Schizophrenia
  • Schizophrenic Psychology
  • Treatment Outcome